MNGI Digestive Health is thrilled to announce that VOQUEZNA (vonoprazan) has been officially approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD) in adults. This exciting development marks a significant advancement in the field of gastrointestinal medicine.
VOQUEZNA, developed by Phathom Pharmaceuticals, is now the first and only FDA-approved treatment of its kind for Non-Erosive GERD, a condition affecting millions of Americans who experience frequent heartburn without esophageal mucosal erosions. This approval is a milestone not just for Phathom but also for the broader GI community, as it introduces a new class of acid suppression therapy to the market.
MNGI Digestive Health played a crucial role in the pivotal PHALCON-NERD-301 study, which was instrumental in obtaining this approval. Conducted in 2021, the study evaluated the efficacy and safety of VOQUEZNA in treating Non-Erosive GERD.
For those interested in being part of future clinical studies and contributing to advancements in digestive health, MNGI Digestive Health continues to conduct research and clinical trials. Patients can learn more about participating in these studies by visiting https://www.mngi.com/our-gi-care/clinical-studies or contacting our research department directly.
For more information about VOQUEZNA and its impact on digestive health, please visit www.voquezna.com.
MNGI Digestive Health remains at the forefront of gastrointestinal research and patient care, committed to improving outcomes and enhancing the quality of life for individuals with digestive disorders. Stay connected with us for more updates on our ongoing research and clinical trials.
